ZIVO Bioscience, Inc. (9R8.SG)
| Previous close | 2.4600 |
| Open | 2.4200 |
| Bid | 2.6400 x N/A |
| Ask | 2.9000 x N/A |
| Day's range | 2.4200 - 2.5000 |
| 52-week range | 2.2000 - 3.2200 |
| Volume | |
| Avg. volume | 2 |
| Market cap | 25.982M |
| Beta (5Y monthly) | 0.25 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ZIVO Bioscience Announces Results of Study with its Product Candidate for the Prevention and Treatment of Coccidiosis in Broiler Chickens
BLOOMFIELD HILLS, Mich., February 10, 2023--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced the results of a four-month study performed by a third party on behalf of a potential partner company, which included a 42-day coccidiosis trial in broiler chickens. The study evaluating the Company’s novel immune-modulating bio
- Business Wire
ZIVO Bioscience Announces Plans for a New Streamlined, Focused Corporate Structure and Establishes the ZIVOLife Agtech Business
BLOOMFIELD HILLS, Mich., October 24, 2022--Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the "Company"), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today announced plans to create ZIVOLife LLC ("ZIVOLife"), a newly formed wholly-owned subsidiary, to streamline the Company’s corporate structure, better capitalize on the global agtech market opportunity and accelerate progress toward generati
- Business Wire
ZIVO Bioscience CEO Issues Letter to Shareholders
BLOOMFIELD HILLS, Mich., September 23, 2022--Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, today issued the following letter to shareholders from its Chairman, President and Chief Executive Officer, John Payne.
